"10.1371_journal.pone.0012031","plos one","2010-08-06T00:00:00Z","Laura A Sullivan; Juliet G Carbon; Christina L Roland; Jason E Toombs; Mari Nyquist-Andersen; Anita Kavlie; Kyle Schlunegger; James A Richardson; Rolf A Brekken","Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Affitech AS, Oslo Research Park, Oslo, Norway; Peregrine Pharmaceuticals, Inc., Tustin, California, United States of America; Departments of Pathology and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America","Conceived and designed the experiments: LAS RAB. Performed the experiments: LAS JGC CLR JET. Analyzed the data: LAS CLR JR RAB. Contributed reagents/materials/analysis tools: LAS MNA AK KS. Wrote the paper: LAS RAB.","R. A. Brekken is a consultant for, has equity interest in, and is a recipient of a sponsored research grant from Peregrine Pharmaceuticals and Affitech AS. R. A. Brekken is also an author of a patent on technology that was used to develop the antibody r84 by Peregrine Pharmaceuticals and Affitech AS. M. Nyquist-Andersen and A. Kavlie are employees of Affitech AS, and K. Schlunegger is an employee of Peregrine Pharmaceuticals, which supported these studies by providing r84, mcr84, and funding. Peregrine and Affitech did not participate in the planning, execution, or interpretation of the experiments. The authors affirm that they will adhere to the PLoS data sharing statement.","2010","08","Laura A Sullivan","LAS",9,TRUE,2,4,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
